Weekly Pharma & Life Science News Round-Up: 10th-14th October
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 10th-14th October 2022.
The PM Society Awards has been running for 37 years. It’s an event in the pharma marketing and healthcare agency calendar that showcases the best creative work our industry has to offer, and an opportunity for networking and celebration.
Orangewood Partners, a long-term focused private investment firm, announces an investment in Barrington James, a leading global recruitment firm that primarily serves the pharmaceutical, biotechnology and medical device sectors.
Zetta Genomics, a pioneer in large-scale data management for genomics, has opened its first international office in the Trinitat neighbourhood of Valencia.
Leicester-based procurement services organisation Unimed Procurement Services has joined forces with International Health Partners to create a long-lasting partnership dedicated to supplying life-saving medical supplies to countries in need.
BIOCORP and Merck KGaA, Darmstadt, Germany, will collaborate on the development and global distribution of a specific version of Mallya for drug delivery devices.
The annual list recognizes companies that have had a positive social impact through activities that are part of their core business strategy. Merck was selected for its work expanding global access to the company’s human papillomavirus (HPV) vaccines.
Medidata has launched the Intelligent Trials Diversity Module to help improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age, and ethnicity.
Thermo Fisher Scientific has expanded its clinical research operations with the opening of a state-of-the-art bioanalytical lab in Richmond, Virginia.
Gerresheimer AG, a leading provide of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, confirms guidance for its financial year 2022 after another quarter of strong and profitable growth.
Sebia announces the acquisition of Zeus Scientific, an In Vitro Diagnostic (IVD) company based in New Jersey (US) specialized in autoimmune and infectious diseases technologies.
Charles River Laboratories International, Inc. announces the launch of its nAAVigation™ Vector Platform (nAAVigation).
Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announces the launch of a new Digital Disease Management Platform to support patients during their treatment journey.
EnterBiotix Limited announces that it has been granted a Manufacturer’s licence for Investigational Medicinal Products (IMP) by the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbiome product candidates for clinical trials.
Evonik has entered into a long-term supply agreement with Phathom Pharmaceuticals, a U.S. biopharmaceutical company focused on developing and commercializing new treatments for gastric acid-related diseases.
The powder and liquid transfer specialist, ChargePoint Technology Group, and leading provider of infection prevention and other procedural products and services, STERIS, have partnered to provide a successful sterile solution to specialty chemicals company, Evonik.
Biopharma Excellence has launched a groundbreaking new Science Huddle panel debate series, with a high-impact first session delving into Small data, big outcomes: strategies for achieving statistical significance when global patient populations are limited.
Florence, a fast-growing tech platform connecting NHS and social care workers with available shifts, announces its expansion into France.
PharmaLex Group, the leading provider of specialised services for the pharma, biotech and MedTech industries worldwide, has announced a merger with UK pharmaceutical and healthcare services consultancy, NeoHealthHub Limited.
TrakCel, the leading supplier of cellular orchestration solutions for clinical trials and commercial therapies to the cell and gene therapy (CGT) industry, announces the signing of a strategic partnership with ZS.
AdAlta Limited and GPCR Therapeutics announce a collaboration to evaluate AdAlta’s CXCR4 inhibiting i-bodies as cancer therapeutics, using GPCR Therapeutics’ proprietary combination inhibition approach.